Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Correspondence] Inhaled triple therapy in chronic obstructive pulmonary disease – Authors’ reply

We thank Eric Marchand for his comment and query. On the basis of previous studies,1,2 Marchand questions whether the withdrawal of inhaled corticosteroids (ICS) in a proportion of patients randomised to a combination of a long-acting β-agonist and a long-acting anticholinergic (LABA/LAMA) in the TRIBUTE study3 could be responsible for the observed difference in moderate-to-severe exacerbation rates. To address this issue, we have done a stratified analysis according to previous use of ICS/LABA and LABA/LAMA in the 2 months before screening.